Top Page
Prophase Labs
(NASDAQ:PRPH)
Prophase Labs (PRPH) vs. SPDR S&P 500 ETF (SPY)
Prophase Labs Business Overview & Revenue Model
Prophase Labs Earnings Call Summary
Prophase Labs Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.08M | 6.77M | 44.38M | 122.65M | 79.04M | 14.51M |
| Gross Profit | 2.06M | -150.00K | 16.24M | 70.65M | 32.81M | 4.61M |
| EBITDA | -24.81M | -32.34M | -14.83M | 28.73M | 11.39M | -1.49M |
| Net Income | -41.70M | -53.36M | -16.78M | 18.46M | 6.27M | -2.13M |
Balance Sheet | ||||||
| Total Assets | 65.70M | 63.20M | 91.93M | 87.65M | 89.30M | 31.41M |
| Cash, Cash Equivalents and Short-Term Investments | 405.00K | 678.00K | 4.74M | 17.44M | 17.51M | 8.46M |
| Total Debt | 7.68M | 24.57M | 18.46M | 6.96M | 14.90M | 14.72M |
| Total Liabilities | 58.84M | 55.85M | 42.54M | 24.02M | 30.67M | 20.85M |
| Stockholders Equity | 6.86M | 7.35M | 49.38M | 63.63M | 58.63M | 10.56M |
Cash Flow | ||||||
| Free Cash Flow | -22.75M | -18.44M | -14.50M | 24.63M | -17.85M | -4.28M |
| Operating Cash Flow | -22.99M | -17.54M | -11.35M | 28.55M | -13.62M | -2.59M |
| Investing Cash Flow | -40.00K | 2.42M | -1.37M | -2.08M | -19.67M | -1.02M |
| Financing Cash Flow | 9.66M | 14.19M | 5.76M | -26.02M | 35.13M | 9.99M |
Prophase Labs Technical Analysis
Prophase Labs Risk Analysis
Prophase Labs Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $25.98M | -0.84 | -50.23% | ― | -15.61% | -68.96% | |
47 Neutral | $19.68M | 65.13 | 0.27% | ― | 75.19% | ― | |
46 Neutral | $5.46M | -0.23 | -37.38% | ― | -22.60% | 53.82% | |
45 Neutral | $8.19M | -1.99 | -93.87% | ― | -0.74% | 81.49% | |
40 Underperform | $13.47M | -0.38 | -44.42% | ― | -1.50% | 80.17% | |
39 Underperform | $517.48K | -0.06 | ― | ― | ― | ― |
Prophase Labs Corporate Events
ProPhase Labs, Inc. announced that it has entered into a non-binding letter of intent for a proposed reverse merger with Advanced Biological Laboratories S.A., a European biotechnology company, under which ABL would become the majority owner of the combined entity. The contemplated transaction, if completed, would significantly reshape ProPhase’s ownership structure and strategic direction by aligning it more closely with ABL’s biotech focus, with potential implications for shareholders and the company’s positioning in the broader healthcare and diagnostics market.
On November 30, 2025, Prophase Labs‘ stockholders approved a reverse stock split of its common stock at a ratio of one share for every ten shares, effective December 2, 2025. This move was aimed at increasing the per-share trading price to meet NASDAQ’s continued listing requirements. The reverse stock split did not alter stockholders’ percentage ownership, except for cash adjustments for fractional shares, and the company’s common stock continues to trade under the symbol ‘PRPH’.
On November 24, 2025, ProPhase Labs, Inc. conducted a Special Meeting of Stockholders where six proposals were presented and approved. The proposals included acquiring digital assets, creating a new class of digital treasury shares, issuing digital tokens, and authorizing stock splits. Proposal 4, concerning stock splits, notably met the approval requirements for charter amendments under Delaware law, indicating strong shareholder support and potential strategic shifts for the company.
On November 21, 2025, ProPhase Labs, Inc. received confirmation from Avtech Capital, LLC to continue its forbearance under an existing equipment lease, with a new payment schedule starting November 28, 2025. This arrangement ensures the company can bring its lease current without affecting its operations, liquidity, or financial reporting, as confirmed by their recent Form 10-Q.
On November 21, 2025, ProPhase Labs, Inc. disclosed that a civil action filed against it in 2023 had been unsealed by court order on November 4, 2025. The unsealing is a procedural step under the False Claims Act, and the company was unaware of the action until November 19, 2025. ProPhase Labs has not been served with the complaint and has received no indication of governmental intervention. The company denies any wrongdoing, maintains its compliance standards, and intends to defend itself vigorously. It also notes that a separate private dispute with Dr. Hennrick was resolved in April 2024. The company does not expect the unsealed matter to impact its operations.
On November 19, 2025, ProPhase Labs announced its strategic initiatives, including M&A discussions and the commercialization of the BE-Smart™ Esophageal Cancer Test following a landmark study. The company is also pursuing a $50 million collection initiative through Crown Medical, which has been appointed as Special Counsel to expedite litigation against insurance carriers. These efforts aim to unlock significant value for ProPhase, which it believes is not reflected in its current share price.
On October 9, 2025, ProPhase Labs, Inc. entered into an At-the-Market Sales Agreement with WestPark Capital, Inc., allowing the company to offer and sell shares of its common stock through the agent. This agreement, underpinned by the company’s effective registration statement and related prospectus, provides ProPhase Labs with flexibility in its stock offerings, potentially impacting its market presence and financial strategy. The agreement includes customary provisions and allows for termination by either party, reflecting a strategic move to manage its capital and shareholder interests.